Doheny Asset Management’s Puma Biotechnology PBYI Stock Holding History

Doheny Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-8,800	Closed	-$870K	–	109
2017 Q4	$870K	Buy	+8,800	New	+$985K	0.41%	64
2015 Q3	–	Sell	-3,025	Closed	-$353K	–	116
2015 Q2	$353K	Sell	3,025 -50	-2%	-$9.05K	0.16%	89
2015 Q1	$726K	Hold	3,075	–	–	0.34%	67
2014 Q4	$582K	Hold	3,075	–	–	0.28%	73
2014 Q3	$734K	Sell	3,075 -19,555	-86%	-$4.02M	0.37%	62
2014 Q2	$1.49M	Buy	+22,630	New	+$1.61M	0.71%	44

Other funds holding PBYI

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Doheny Asset Management's PBYI Position: Q1 2018 in Review

Doheny Asset Management sold out of Puma Biotechnology (PBYI) in Q1 2018, closing a stake of 8,800 shares — an estimated $870K sold.

Doheny Asset Management first reported a position in PBYI in Q2 2014 and held it in 6 quarters. The position peaked at $1.49M in Q2 2014. 178 funds tracked by Wall St. Rank hold PBYI as of Q1 2018.

Doheny Asset Management reported no remaining Puma Biotechnology position as of Q1 2018 after selling out during the quarter.
Doheny Asset Management sold 8,800 Puma Biotechnology shares in Q1 2018, an estimated $870K.
Doheny Asset Management first reported a position in Puma Biotechnology in Q2 2014 and held it in 6 quarters.
Doheny Asset Management's Puma Biotechnology position peaked at $1.49M in Q2 2014.
178 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2018.

Based on Doheny Asset Management's 13F filing for Q1 2018, filed 17 May 2018.